Oncology companies develop therapies, diagnostics and technologies that support the detection, monitoring and treatment of cancer. The sector is one of the largest and most active areas of biotechnology and pharmaceutical innovation.
This category includes companies working on:
Browse 291 UK oncology companies below.
TCR bispecific immunotherapies for cancer and infectious disease
Immunocore is a commercial-stage biopharma developing T cell receptor bispecific immunotherapies. Its lead product tebentafusp received FDA approval in 2022 for metastatic uveal melanoma and generated $400 million in revenue in 2025. Three Phase 3 trials are enrolling across melanoma indications, with topline data…
Oncology drug discovery and IP licensing from rural Wales
Morvus Technology is a privately owned pharmaceutical company engaged in the discovery, development, and out-licensing of novel oncology drugs and platform technologies. The company's portfolio includes ProTide nucleoside chemistry, out-licensed to NuCana plc for clinical development; an inhaled anti-tumour agent for…
AI-designed antibody biologics adapting human therapeutics for companion animals
Antigenesis Biologics is a biotechnology company developing targeted biological treatments for companion animals, applying expertise in human antibody therapeutics to address a gap between human and veterinary healthcare innovation. The company uses AI and computational design approaches to develop antibody-based…
Microfluidic 3D disease models for preclinical drug screening
ScreenIn3D is a biotechnology company and contract research organisation providing drug screening using three-dimensional human cell and tissue models. Its microfluidic platform supports tumour spheroids, organoids and co-cultures, enabling researchers to assess candidate efficacy, toxicity and drug combinations from…
In vitro immunology CRO for pre-clinical drug development
Immundnz is a contract research organisation specialising in in vitro immunology services for pharmaceutical and biotechnology clients. The company designs and applies customised and standard immunological assays to assess immune safety, efficacy, and response to candidate therapeutics during pre-clinical development.…
Semiconductor biosensors for blood-based cancer biomarker detection
ExoNostic is a diagnostic technology company developing semiconductor biosensors for cancer biomarker detection. Its investigational lab-on-a-chip platform is designed to identify molecular signatures in small blood samples, combining sensor-based measurements with computational interpretation. An Innovate UK-funded…
Pre-cancer intervention to prevent cancer before it develops
Omos Biosciences is an early-stage biotechnology company developing approaches to cancer prevention through intervention at the pre-cancerous stage, rather than treatment of established disease. The company's strategy builds on established precedents in early cancer prevention, such as polyp removal to prevent…
mRNA vaccine manufacturer and R&D partner
Moderna is a company developing and manufacturing mRNA-based medicines and vaccines across infectious disease, oncology and rare disease. Its UK Innovation and Technology Centre, opened at Harwell in September 2025, is the first facility in the UK capable of onshore mRNA vaccine manufacturing, with capacity for up to…
Cell-free DNA capture reagents for liquid biopsy and cancer diagnostics
BIOCAPTIVA is a biotechnology company developing novel cell-free DNA capture technology to improve liquid biopsy for cancer research and diagnostics. Its proprietary polymer platform captures cfDNA directly from whole blood without centrifuges or additional reagents, delivering substantially higher cfDNA yields than…
Next-generation targeted protein degradation therapeutics
Amphista Therapeutics is a Cambridge-based biopharmaceutical company developing next-generation targeted protein degradation medicines. Its proprietary platform generates bifunctional small molecule degraders that harness a broader range of the cell's protein-degrading machinery than existing approaches, enabling…
Hypoxia-activated CAR-T cell therapy platform for solid tumour cancers
Korecyte Bio is a preclinical-stage cell therapy company developing HypoxiCAR, a modular CAR-T platform for treating solid tumours. The technology uses a dual-sensor genetic switch that keeps engineered T-cells dormant in healthy tissue and activates them only within the low-oxygen environment typical of solid…
Cyclic peptide screening platform for first-in-class cancer drugs
Curve Therapeutics is a drug discovery company using its proprietary platform to identify first-in-class small molecule therapeutics against targets that have been difficult to address using conventional methods. The platform screens gene-encoded cyclic peptide libraries inside mammalian cells to identify functionally…
Oncolytic virus platform for tumour-targeted cancer immunotherapy
Accession Therapeutics is a clinical-stage biotechnology company developing tumour-targeted immunotherapies based on its proprietary oncolytic virus platform. Designed for systemic delivery, the platform selectively replicates within cancer cells to generate therapeutic payloads locally at the tumour site. The…
Preclinical immunology CRO for drug discovery programmes
Nexus BioQuest is a contract research organisation specialising in preclinical immunology services for the biotechnology and pharmaceutical industries. The company offers bespoke assay development and in vitro screening across immuno-oncology, autoimmunity, inflammation, and neuroinflammation, including cytokine…
Phosphoproteomics platform for kinase activity profiling and precision oncology
Kinomica is a UK precision medicine company developing phosphoproteomics technology for drug discovery and companion diagnostics. Its platform combines LC-MS/MS mass spectrometry with proprietary bioinformatics to measure kinase activity directly from patient samples, enabling drug target identification, monitoring of…
Clinical-stage developer of oncolytic immunotherapies for cancer treatment
Replimune is the UK research and development site of Replimune Group, a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer. Its platform uses genetically engineered herpes simplex viruses to selectively replicate within and destroy tumour cells, releasing tumour antigens and…
Quantitative digital pathology image analysis services for pharma
OracleBio is a contract research organisation specialising in quantitative digital pathology and histopathology image analysis. The company delivers high-precision tissue biomarker quantification services to pharmaceutical and biotechnology clients, supporting pre-clinical and clinical research programmes. Services…
Full-service CRO delivering clinical trial and regulatory support services
Optimapharm is a contract research organisation providing clinical trial management and observational study services to pharmaceutical, biotech and medical device companies. The company supports trials from Phase I through Phase IV, offering regulatory affairs, medical writing, clinical monitoring, data management,…
3D-bioprinted patient-derived tumour models for oncology drug screening
Carcinotech is a contract research and tumour model manufacturing company that produces 3D-bioprinted micro-tumours for preclinical oncology drug screening and personalised medicine testing. Using patient-derived biopsies, primary cells, immune cells, and cancer stem cells, its platform generates assay-ready living…
AI platform integrating biology, chemistry and automation for drug discovery
Recursion is a clinical-stage biotechnology company using AI and robotic wet-lab automation to industrialise small molecule drug discovery. Its platform integrates phenomics, transcriptomics, proteomics and patient data to identify and optimise drug candidates at scale. Following its acquisition of Oxford-based…